Tags

Type your tag names separated by a space and hit enter

Abaloparatide: A new pharmacological option for osteoporosis.
Am J Health Syst Pharm. 2019 Jan 25; 76(3):130-135.AJ

Abstract

Purpose

The efficacy and safety of abaloparatide, a parathyroid hormone-related protein analog for the treatment of osteoporosis in postmenopausal women at high fracture risk, is reviewed.

Summary

A MEDLINE search was conducted for full text English-language articles, using the terms abaloparatide, parathyroid hormone, and osteoporosis. Published articles pertinent to the short- and long-term efficacy and safety of abaloparatide among postmenopausal women with osteoporosis were reviewed and summarized. Based on randomized, placebo-controlled and active-comparator studies, abaloparatide can reduce the risk of new vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. Abaloparatide can also significantly increase bone mineral density (BMD) at the total hip, femoral neck, and lumbar spine. Patients receiving abaloparatide experience faster and more robust changes in BMD compared to those receiving teriparatide. Overall, abaloparatide is well tolerated with a mild adverse effect profile, including dizziness, headache, nausea, and palpitations. Additionally, there is a lower incidence of hypercalcemia with abaloparatide than with teriparatide. At this time, the differences demonstrated between abaloparatide and teriparatide would not be considered clinically significant. Larger and more robust studies are needed to determine future clinical significance of abaloparatide compared with other agents for use in the postmenopausal osteoporotic population.

Conclusion

Abaloparatide is an effective anabolic agent to improve bone formation and resorption amongst postmenopausal women with osteoporosis. Based on its clinical evidence, abaloparatide can result in greater BMD increases and less hypercalcemia compared with the only current marketed anabolic agent, teriparatide. Adverse events associated with abaloparatide are generally mild in nature and include nausea, dizziness, headache, and palpitations.

Authors+Show Affiliations

Department of Pharmacy, University Health Care System, Augusta, GA.Department of Pharmacy Practice, Presbyterian College School of Pharmacy, Clinton, SC.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30689744

Citation

Sleeman, Allyson, and Jennifer N. Clements. "Abaloparatide: a New Pharmacological Option for Osteoporosis." American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists, vol. 76, no. 3, 2019, pp. 130-135.
Sleeman A, Clements JN. Abaloparatide: A new pharmacological option for osteoporosis. Am J Health Syst Pharm. 2019;76(3):130-135.
Sleeman, A., & Clements, J. N. (2019). Abaloparatide: A new pharmacological option for osteoporosis. American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists, 76(3), 130-135. https://doi.org/10.1093/ajhp/zxy022
Sleeman A, Clements JN. Abaloparatide: a New Pharmacological Option for Osteoporosis. Am J Health Syst Pharm. 2019 Jan 25;76(3):130-135. PubMed PMID: 30689744.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Abaloparatide: A new pharmacological option for osteoporosis. AU - Sleeman,Allyson, AU - Clements,Jennifer N, PY - 2019/1/29/entrez PY - 2019/1/29/pubmed PY - 2019/6/30/medline SP - 130 EP - 135 JF - American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists JO - Am J Health Syst Pharm VL - 76 IS - 3 N2 - Purpose: The efficacy and safety of abaloparatide, a parathyroid hormone-related protein analog for the treatment of osteoporosis in postmenopausal women at high fracture risk, is reviewed. Summary: A MEDLINE search was conducted for full text English-language articles, using the terms abaloparatide, parathyroid hormone, and osteoporosis. Published articles pertinent to the short- and long-term efficacy and safety of abaloparatide among postmenopausal women with osteoporosis were reviewed and summarized. Based on randomized, placebo-controlled and active-comparator studies, abaloparatide can reduce the risk of new vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. Abaloparatide can also significantly increase bone mineral density (BMD) at the total hip, femoral neck, and lumbar spine. Patients receiving abaloparatide experience faster and more robust changes in BMD compared to those receiving teriparatide. Overall, abaloparatide is well tolerated with a mild adverse effect profile, including dizziness, headache, nausea, and palpitations. Additionally, there is a lower incidence of hypercalcemia with abaloparatide than with teriparatide. At this time, the differences demonstrated between abaloparatide and teriparatide would not be considered clinically significant. Larger and more robust studies are needed to determine future clinical significance of abaloparatide compared with other agents for use in the postmenopausal osteoporotic population. Conclusion: Abaloparatide is an effective anabolic agent to improve bone formation and resorption amongst postmenopausal women with osteoporosis. Based on its clinical evidence, abaloparatide can result in greater BMD increases and less hypercalcemia compared with the only current marketed anabolic agent, teriparatide. Adverse events associated with abaloparatide are generally mild in nature and include nausea, dizziness, headache, and palpitations. SN - 1535-2900 UR - https://www.unboundmedicine.com/medline/citation/30689744/Abaloparatide:_A_new_pharmacological_option_for_osteoporosis_ L2 - https://academic.oup.com/ajhp/article-lookup/doi/10.1093/ajhp/zxy022 DB - PRIME DP - Unbound Medicine ER -